Abstract: In certain aspects the invention features novel compositions and pharmaceutical preparations of the same. In certain embodiments, the compositions comprise ?- and/or ?-boswellic acid and/or their C-acetates in an amount greater than 65% by weight.

Abstract: The present invention relates to extracts of curcuma species plant material using supercritical CO2 extraction methods, methods of treating a subject suffering from suffering from amyloid plaque aggregation or fibril formation associated with, for example, Alzheimer's disease, and methods of inhibiting amyloid plaque aggregation or fibril formation in tissue thereof.

Abstract: An aspect of the present invention relates to compositions comprising a gingerol, for example, compositions comprising gingerol in an amount greater than about 2% by weight. In some aspects of the invention, the composition comprises 6-gingerol, 8-gingerol, 10-gingerol, 6-shagaol, or combinations thereof. Another aspect of the invention relates to a method for extracting a ginger species comprising, sequentially extracting a ginger species plant material to yield an essential oil fraction, a gingerol fraction, a phenolic fraction, and a polysaccharide fraction, wherein the essential oil and gingerol fractions are derived by extracting plant feedstock material by supercritical carbon dioxide extraction, the phenolic fraction is extracted from the plant feedstock material or from the remainder of the essential oil and gingerol extractions by hydroalcoholic extraction, and the polysaccharide fraction is derived by water extraction of the remainder of the phenolic extraction.

Abstract: The present invention comprises methods for making compositions derived from Ilex species, particularly Ilex paraguariensis, having lowered caffeine and tannin concentrations, compositions made by such methods, oral delivery formulations, and methods of use of such compositions. In particular, the present invention comprises methods for making maté compositions that have a predetermined characeteristic, such as a lowered amount of caffeine, elevated amounts of caffeoyls, and/or lowered amounts of tannin compounds compared to the native maté plant materials. Further, the invention comprises methods of additional processing steps tp produce compositions having a predetermined alkaloid ratio or profiles to meet particular considerations for final products. The compositions of the present invention may be processed for specific uses such as tablets or other oral delivery vehicles. These compositions may be used in methods for treatment of physiological and medical conditions.

Abstract: The present invention comprises methods and compositions comprising Areca extract compositions and compositions comprising extracts of Ilex paraguariensis or theobromine. Methods of the invention comprise methods of making pharmaceutical or nutriceutical products comprising Areca catechu extract compositions and maté extract compositions or theobromine, and methods of use of the extracted products and pharmaceutical and nutriceutical products. The present invention also comprises methods for treating conditions related to mental and physical fatigue and obesity, as well as, enhancement of mental focus, cognition, and a sense of well being, comprising administering the compositions of the present invention.

Abstract: The present invention comprises methods for making compositions derived from Ilex species, particularly Ilex paraguariensis, having lowered caffeine and tannin concentrations, compositions made by such methods, oral delivery formulations, and methods of use of such compositions. In particular, the present invention comprises methods for making maté compositions that have a predetermined characeteristic, such as a lowered amount of caffeine, elevated amounts of caffeoyls, and/or lowered amounts of tannin compounds compared to the native maté plant materials. Further, the invention comprises methods of additional processing steps to produce compositions having a predetermined alkaloid ratio or profiles to meet particular considerations for final products. The compositions of the present invention may be processed for specific uses such as tablets or other oral delivery vehicles. These compositions may be used in methods for treatment of physiological and medical conditions.